Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Worries Over Blockbuster Meds Avandia, Fosamax

Diabetes drug Avandia linked to fractures, while bone drug Fosamax is tied to irregular heartbeat

By Amanda Gardner
HealthDay Reporter


Related Encyclopedia
 border=
Addison's Disease
Alzheimer's Disease
Aneurysms
Angina Pectoris
More...

Related Healthscout Videos
 border=
Monitoring Diabetes
Patients And Doctors Discuss The I-Port
Traditional Insulin Delivery Methods
What Is Diabetes
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Diabetes
More...

Related Drug Information
 border=
Accupril
Actonel
Actos
Altace
More...

Related News Articles
 border=
Work Strife Stresses the Heart
Abnormal Heartbeat After Bypass a Bad Sign
Lowered HRT Use May Have Cut Heart Attacks
With Peripheral Artery Disease, Med Adherence Is Low
More...

MONDAY, April 28 (HealthDay News) -- Avandia and Fosamax, widely prescribed drugs used to treat two common health conditions, show further evidence of being linked to adverse events.

One study finds that long-term use of thiazolidinediones -- a family of diabetes drugs that includes blockbuster Avandia -- appears to be linked with an increased risk for bone fractures.

Text Continues Below



And a second study found that Fosamax, used to prevent fractures in women with osteoporosis, may be associated with a higher risk of atrial fibrillation, a type of abnormal heart rhythm.

Both studies were published in the April 28 issue of the Archives of Internal Medicine.

Avandia (rosiglitazone) and Actos (pioglitazone), both thiazolidinediones, now account for 21 percent of all oral anti-diabetic drugs prescribed in the United States. An estimated 3.5 million or more U.S. patients take Avandia, experts say.

But in 2007, Avandia and four other drugs from the same class were given a "black box" warning, cautioning users of an increased of heart problems.

The current study, led by Dr. Christian Meier of University Hospital Basel, Switzerland, looked at links between thiazolidinediones and fracture. It was designed to ascertain whether only women were affected and where fractures were most likely to occur. The research involved 1,020 men and women aged 30 to 89 who had sustained a fracture while taking Avandia, Actos, insulin or another anti-diabetic drug.

Compared to controls, individuals taking Avandia or Actos had more than double the risk of fractures, with the risk with Actos being slightly higher than with Avandia. Drug-associated fractures were particularly common at the wrist and hip. Both men and women were at risk, and the odds for fracture tended to rise with dose of drug taken.

The odds of sustaining a fracture were heightened in patients taking Avandia or Actos for 12 to 18 months and highest in those who were on the medication for two or more years.

Page:  1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/28/2008

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





SOURCES: Spyros G.E. Mezitis, M.D., Ph.D., endocrinology consultant and clinical investigator at Lenox Hill Hospital, and clinical assistant professor of medicine, NewYork-Presbyterian Hospital/Cornell Medical Center, New York City; Nancy Pekarek, spokeswoman, GlaxoSmithKline; Ronald Rogers, spokesman, Merck & Co. Inc.; April 28, 2008, Archives of Internal Medicine; March 11, 2008, British Medical Journal


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map